NBTX Nanobiotix S.A.

FDA Catalyst Company
5.39
0  0%
Previous Close 5.39
Open
52 Week Low 4.65
52 Week High 18
Market Cap $187,867,809
Shares 34,854,881
Float 34,854,881
Enterprise Value $143,459,427
Volume 40
Av. Daily Volume 1,784
Live cash est $88,666,444,222
Cash Burn N/A
No. Mths Cash 12
Insiders % 0.2
Total debt to equity 4.35
Earnings Date 01/01/2001
EPS 1.82
Rev guidance $10,459,000,000

Biotech Analyst Ratings

Analyst Action Rating Now PT Prior PT Now Last Updated
Evercore ISI Group Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 01/06/2021

Latest News

  1. Regulatory News:

    NANOBIOTIX (NASDAQ:NBTX, Company", ))), a clinical-stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that Laurent Levy, co-founder and chairman of the executive board, and Bart Van Rhijn, chief financial officer, will participate in the following conferences:

    UBS Global Healthcare Conference

    • Presentation Date: Monday, May 23rd, 2022
    • Time: 10:45 AM ET
    • Location: New York, New York, USA

    H.C. Wainwright Global Investment Conference

    • Presentation Date: Wednesday, May 25th, 2022
    • Time: 8:30 AM ET
    • Location: Virtual and Miami, Florida, USA

    A live audio webcast of each presentation will be available on the events page of the Investors…

    View Full Article
  2. In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulations of the Autorité des Marchés Financiers (French Financial Markets Authority)

    Regulatory News:

    Nanobiotix (PARIS:NANO) (NASDAQ:NBTX):

    Market: Euronext Paris / Nasdaq
    Euronext Compartment: B
    ISIN code: FR0011341205
    Nasdaq: NBTX
    Bloomberg: NANO:FP
    Reuters: NANO.PA
    Website: www.nanobiotix.com

    Date

    Number of Shares
    Outstanding

     

    Total number of voting rights

    Total voting rights,
    gross (1)

     

    Total voting rights,
    net (2)

    April 30, 2022

    34,875,872

    36,392,064

    36,371,073

    (1) The total number of gross (or "theoretical") voting rights is used as the basis for calculating threshold crossings. In accordance with

    View Full Article
  3. Regulatory News:

    NANOBIOTIX (NASDAQ:NBTX), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that it will report its financial results for the first quarter of 2022 ending March 31, 2022, on Wednesday, May 18, 2022, after the close of the US market.

    The announcement will be followed by a conference call and live audio webcast on Thursday, May 19, 2022, at 8:00 AM EDT / 2:00 CET, prior to the opening of the US market. During the call, Laurent Levy, chief executive officer, and Bart Van Rhijn, chief financial officer, will briefly review the Company's first quarter results and provide an update on operational activities before taking questions…

    View Full Article
  4. Regulatory News:

    NANOBIOTIX (NASDAQ:NBTX), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced the presentation of three abstracts featuring potential first-in-class radioenhancer NBTXR3 at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting from June 3-7.

    "We are aiming to significantly improve outcomes for patients with cancer through NBTXR3, and to do so we must validate the safety and efficacy of our innovation across solid tumor indications and in combination with existing treatment modalities," said Laurent Levy, co-founder and chief executive officer of Nanobiotix. "Taken together with data we have previously reported…

    View Full Article
  5. Data presented at the 2022 Annual Meeting of the American Association of Cancer Research

    • New data from an open-label preclinical study in mice evaluating the changes in immune-related genes induced by multiple combinations of NBTXR3, anti-PD-1, anti-LAG-3, and anti-TIGIT showed that groups that received NBTXR3 along with checkpoint inhibitors outperformed all other combinations in efficacy, survival, and induction of long-term anti-cancer memory
    • This new analysis concluded that NBTXR3 plus a triple blockade of PD-1, LAG-3, and TIGIT (Combination therapy) promotes immune activation at the irradiated site, abscopal responses at non-irradiated sites, and suggests that the Combination therapy may be effective against metastatic cancers

    Regulatory…

    View Full Article
View All Nanobiotix S.A. News